A carregar...
Regorafenib adjusted dose for Chilean patients with chemoresistant metastatic colorectal cancer: a case series
BACKGROUND: Regorafenib is a therapeutic alternative for patients with metastatic colorectal cancer (MCRC) resistant to conventional therapies. The reported toxicity is relevant and there is no data on Latin American patients. The objective was to evaluate the overall survival (OS), progression-free...
Na minha lista:
| Publicado no: | Ecancermedicalscience |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Cancer Intelligence
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6214673/ https://ncbi.nlm.nih.gov/pubmed/30483355 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3332/ecancer.2018.875 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|